Overall rank by patents
#11,528
Across all tracked assignees
USPTO PatentsView assignee record - 26 granted patents across 15 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Allergan holds 26 US patents across 15 technology areas, rank #11,528 of 50,000 tracked assignees.
Allergan Sales, Llc has been granted 26 US utility patents between 2015 and 2024, placing Allergan Sales, Llc at rank #11,528 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.7 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Allergan Sales, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Allergan sits between ACE Light & Electronic TECH (ningbo) Co., Ltd. (26 patents, rank #11,524) and Amobee, Inc. (26 patents, rank #11,532) - the closest US assignees by grant volume. The composite Innovation Score of 34.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 11 grants, compared with 15 in the 2015–2019 window, a -27% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Allergan Sales, Llc's 11.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Allergan Sales, Llc against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ACE LIGHT & ELECTRONIC TECH (NINGBO) CO., LTD.
26 patents
ADAPTIX LTD
26 patents
AIMPOINT AB
26 patents
ALD VACUUM TECHNOLOGIES GMBH
26 patents
ALLSTATE SOLUTIONS PRIVATE LIMITED
26 patents
AMERICAN HONDA MOTOR CO., INC.
26 patents
AMNEAL PHARMACEUTICALS LLC
26 patents
AMOBEE, INC.
26 patents
ALLERGAN SALES, LLC
26 patents
What this shows Allergan holds 26 patents at rank #11,528, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #11,528 in granted patent volume.
Other assignees with the most granted patents in Allergan's primary technology class.
Allergan's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 54% higher than 46% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 7.7% |
| 2016 | 1 | 3.8% |
| 2017 | 2 | 7.7% |
| 2018 | 3 | 11.5% |
| 2019 | 7 | 26.9% |
| 2020 | 1 | 3.8% |
| 2021 | 6 | 23.1% |
| 2022 | 1 | 3.8% |
| 2024 | 3 | 11.5% |
Top 15 of 15 technology areas
Overall rank by patents
#11,528
Across all tracked assignees
34.0 out of 100
How to use this portfolio
Allergan's 26 grants land it in the top 54% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.